FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome.

Felix Schmitt-HoffnerSjoerd van RijnUmut H ToprakMonika MauermannFelix RosemannAnke Heit-MondrzykJens-Martin HübnerAylin CamgözSabine HartliebStefan M PfisterKai-Oliver HenrichFrank WestermannMarcel Kool

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

The stabilization of MYCN by FOXR2 represents an alternative mechanism to MYCN amplification to increase MYCN protein levels. As such, FOXR2 expression identifies another subset of neuroblastoma patients with unfavorable clinical outcome.

Keyphrases

genome wide
binding protein
poor prognosis
protein protein
amino acid
label free